Long‐Term Results of Autologous Hematopoietic Cell Transplantation (Auto‐HCT)—Real‐Life Data of 15‐ and 20‐Year Survivals From a Single Center
Kajetan Karaszewski, Jakub Góra, Monika Paluszewska, Elżbieta Urbanowska, Ewa Karakulska‐Prystupiuk, Piotr Boguradzki, Agnieszka Tomaszewska, Grzegorz Władysław Basak, Wiesław Wiktor JędrzejczakABSTRACT
Over the years, autologous hematopoietic cell transplantation (auto‐HCT) has become one of the most important therapeutic methods of contemporary hematology. However, analyses of survival after treatment are usually limited to 5‐10 years. Data on longer survival are limited due to difficulties and loss in follow‐up, as well as organizational and personnel changes in transplant centers. Therefore, our study aimed to evaluate the 15‐ and 20‐year overall and progression‐free survival of the recipients of auto‐HCT in our center without exclusion of salvage indications and patients with comorbidities. During the period ranging from 1999 to 2014, there were 452 recipients of auto‐HCT. Survival analyses were performed using Kaplan–Meier curves, the Cox proportional hazards model, and the log‐rank test. First, the entire cohort was evaluated for 15‐ and 20‐year overall and progression‐free survival. Then, similar analyses were performed for subgroups of patients with more frequent indications, including multiple myeloma, AL amyloidosis, Hodgkin lymphoma (HL), non‐Hodgkin lymphomas (NHLs), and acute myeloid leukemia. It was found that after 10 years, both overall and progression‐free survival slowly but gradually declined. Still, a significant proportion of transplanted patients survived 20 years following auto‐HCT, confirming the ability to cure in at least some cases of these earlier incurable disorders.